MXPA03005937A - Compuestos farmaceuticamente activos. - Google Patents

Compuestos farmaceuticamente activos.

Info

Publication number
MXPA03005937A
MXPA03005937A MXPA03005937A MXPA03005937A MXPA03005937A MX PA03005937 A MXPA03005937 A MX PA03005937A MX PA03005937 A MXPA03005937 A MX PA03005937A MX PA03005937 A MXPA03005937 A MX PA03005937A MX PA03005937 A MXPA03005937 A MX PA03005937A
Authority
MX
Mexico
Prior art keywords
cyclic guanosine
phosphodiesterase inhibitors
monophosphate phosphodiesterase
monophosphate
guanosine
Prior art date
Application number
MXPA03005937A
Other languages
English (en)
Spanish (es)
Inventor
James Rawson David
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA03005937A publication Critical patent/MXPA03005937A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MXPA03005937A 2001-03-16 2002-03-04 Compuestos farmaceuticamente activos. MXPA03005937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0106661.2A GB0106661D0 (en) 2001-03-16 2001-03-16 Pharmaceutically active compounds
PCT/IB2002/000659 WO2002074774A1 (en) 2001-03-16 2002-03-04 Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
MXPA03005937A true MXPA03005937A (es) 2003-09-10

Family

ID=9910932

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005937A MXPA03005937A (es) 2001-03-16 2002-03-04 Compuestos farmaceuticamente activos.

Country Status (10)

Country Link
EP (1) EP1368352B1 (enExample)
JP (1) JP2004523585A (enExample)
AT (1) ATE283856T1 (enExample)
BR (1) BR0208154A (enExample)
CA (1) CA2439528A1 (enExample)
DE (1) DE60202134T2 (enExample)
ES (1) ES2231667T3 (enExample)
GB (1) GB0106661D0 (enExample)
MX (1) MXPA03005937A (enExample)
WO (1) WO2002074774A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
CN100374441C (zh) * 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2,3-d]嘧啶-4-酮衍生物,其制备方法及其制药用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
AU2004274403A1 (en) * 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
US7485637B2 (en) 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
WO2006082001A1 (en) 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1
BRPI0608381A2 (pt) * 2005-02-18 2009-12-29 Surface Logix Inc compostos aprimorados farmacocineticamente
AU2006315436A1 (en) 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
ATE464289T1 (de) * 2005-11-16 2010-04-15 Hoffmann La Roche Neues verfahren zur herstellung von thoc
US8071765B2 (en) * 2006-12-21 2011-12-06 Topharman Shanghai Co., Ltd. Process for the preparation of sildenafil and intermediates thereof
KR20100016270A (ko) * 2007-05-11 2010-02-12 산텐 세이야꾸 가부시키가이샤 비맥각계의 선택적 d2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
TWI393578B (zh) 2009-07-07 2013-04-21 瑞健集團股份有限公司 注射裝置
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
TWI557121B (zh) 2011-04-21 2016-11-11 原真股份有限公司 新穎激酶抑制劑
AU2012244550C1 (en) * 2011-04-21 2017-06-22 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN106029647A (zh) * 2013-12-20 2016-10-12 拜耳制药股份公司 葡萄糖转运抑制剂
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
KR102862562B1 (ko) 2015-11-16 2025-09-19 토파두르 파마 아게 포스포디에스테라제 억제제로서 2-페닐-3,4-디하이드로피롤로[2,1-f][1,2,4]트리아지논 유도체 및 이의 용도
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
HK1049834A1 (zh) * 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4,3-d]嘧啶-7-酮类化合物

Also Published As

Publication number Publication date
ES2231667T3 (es) 2005-05-16
JP2004523585A (ja) 2004-08-05
ATE283856T1 (de) 2004-12-15
CA2439528A1 (en) 2002-09-26
GB0106661D0 (en) 2001-05-09
DE60202134D1 (en) 2005-01-05
DE60202134T2 (de) 2005-11-24
EP1368352A1 (en) 2003-12-10
BR0208154A (pt) 2004-03-02
WO2002074774A1 (en) 2002-09-26
EP1368352B1 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
DE60202134D1 (en) Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
CA2287552A1 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
AU5995699A (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
AP2002002455A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
MXPA03006310A (es) Compuestos farmaceuticamente activos.
ATE298753T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung der sexuellen dysfunktion
CA2322900A1 (en) 2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors
BR0004779A (pt) Compostos farmaceuticamente ativos
MY132106A (en) New pyridazin-3(2h)-one derivatives
WO2002064590A3 (en) Carboline derivatives
MY135909A (en) Treatment of pulmonary hypertension
MY140674A (en) New crystalline form of a triazolo(4,5-d)pyrimidine compound
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
WO2002064591A3 (en) Carboline derivatives
CA2413510A1 (en) Condensed pyrazindione derivatives
WO2002079203A8 (en) Imidazo-triazine derivatives as pde 5 inhibitors
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AP2002002462A0 (en) Pharmaceutically active compounds.
EP1241170A3 (en) Pyrazolopyrimidine derivatives
DE60226970D1 (de) Pyrazinoä1',2':1,6ü-pyridoä3,4-bü indole-1,4-dionderivate
GB0000561D0 (en) Treatment of diabetic ulcers
MY131573A (en) Use of pde5 inhibitors for the treatment of premature ejaculation